727 related articles for article (PubMed ID: 20873251)
21. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
Ratjen F; Döring G; Nikolaizik WH
Lancet; 2001 Sep; 358(9286):983-4. PubMed ID: 11583754
[TBL] [Abstract][Full Text] [Related]
22. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
23. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
24. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
[TBL] [Abstract][Full Text] [Related]
25. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M
Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
[TBL] [Abstract][Full Text] [Related]
26. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
[No Abstract] [Full Text] [Related]
27. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
[TBL] [Abstract][Full Text] [Related]
28. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics.
Hasan MA; Lange CF
J Aerosol Med; 2007; 20(3):282-93. PubMed ID: 17894535
[TBL] [Abstract][Full Text] [Related]
29. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
[TBL] [Abstract][Full Text] [Related]
30. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Assael BM
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
32. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
Bilton D; Henig N; Morrissey B; Gotfried M
Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
[TBL] [Abstract][Full Text] [Related]
33. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
34. Inhaled tobramycin (TOBI).
Bonsignore CL
Pediatr Nurs; 1998; 24(3):258-9. PubMed ID: 9987427
[TBL] [Abstract][Full Text] [Related]
35. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Gappa M; Steinkamp G; Tümmler B; von der Hardt H
Scand J Gastroenterol Suppl; 1988; 143():74-6. PubMed ID: 3164515
[TBL] [Abstract][Full Text] [Related]
36. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
Antoniu S
Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis.
Iles R; Legh-Smith J; Drummond M; Prevost A; Vowler S
J Cyst Fibros; 2003 Sep; 2(3):120-8. PubMed ID: 15463860
[TBL] [Abstract][Full Text] [Related]
38. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin.
Vecellio L; Abdelrahim ME; Montharu J; Galle J; Diot P; Dubus JC
J Cyst Fibros; 2011 Mar; 10(2):86-92. PubMed ID: 21075063
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
40. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Moriarty TF; McElnay JC; Elborn JS; Tunney MM
Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]